Breakthrough Pain in Cancer Patients

Clinical Oncology

Volumn 23, Issue 6, 2011, Pages 393-398

  Zeppetella, G ^a  

^a St Clare Hospice   (United Kingdom)

Author keywords

Breakthrough pain; Cancer; Opioids; Pain; Transmucosal

Indexed keywords

ABSTRAL; ANALGESIC AGENT; FENTANYL; FENTANYL CITRATE; MORPHINE; ONSOLIS; OPIATE; PLACEBO; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANALGESIA; ANXIETY; ARTICLE; BONE METASTASIS; BONE PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CRYOTHERAPY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; HYPERTHERMIC THERAPY; INCIDENT PAIN; INTRACRANIAL HYPERTENSION; LIFESTYLE MODIFICATION; MASSAGE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAROXYSMAL NEUROPATHIC PAIN; PATIENT PARTICIPATION; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; RELAXATION TRAINING; SPONTANEOUS PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN;

EID: 79959706638     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2010.12.002     Document Type: Article

References (40)

1. Schrijvers D. Pain control in cancer: recent findings and trends. Ann Oncol 2007, 18(Suppl. 9):ix37-ix42.
2. Cancer pain relief 1996, World Health Organization, World Health Organization, Geneva. 2nd ed.
3. Hanks G.W., Hawkins C. Agreeing a gold standard in the management of cancer pain: the role of opioids. The effective management of cancer pain. UK Key Advances in Clinical Practice Series 2000 2000, 57-77. Aesculapius Medical Press, London. R. Hillier, I. Finlay, J. Welsh, A. Miles (Eds.).
4. Zeppetella G., Ribeiro M.D.C. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 2003, 4:493-502.
5. Portenoy R.K., Hagen N.A. Breakthrough pain: definition, prevalence and characteristics. Pain 1990, 41:273-281.
6. Zeppetella G., O'Doherty C.A., Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 2001, 15:243-246.
7. Portenoy R.K., Bennett D.S., Rauck R., et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic non cancer pain. J Pain 2006, 7:583-591.
8. Colleau S.M. The significance of breakthrough pain in cancer. Cancer Pain Release 1999, 12:1-3.
9. Caraceni A., Portenoy R.K. An international survey of cancer pain characteristics and syndromes: IASP Task Force on Cancer Pain, International Association for the Study of Pain. Pain 1999, 82:263-274.
10. Davies A.N., Dickman A., Reid C., Stevens A.M., Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009, 13:331-338.
11. Hanks G.W., Portenoy R.K., MacDonald N., Forbes K. Difficult pain problems. Oxford textbook of palliative medicine 1998, 454-477. Oxford University Press, Oxford. D. Doyle, G.W. Hanks, N. MacDonald (Eds.).
12. Mercadante S., Maddaloni S., Roccella S., Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992, 50:151-155.
13. Portenoy R.K., Payne D., Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999, 81:129-134.
14. Hwang S.S., Chang V.T., Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003, 101:55-64.
15. Abernethy A.P., Wheeler J.L., Fortner B.V. A health economic model of breakthrough pain. Am J Manag Care 2008, 14:S129-S140.
16. Mercadante S., Villari P., Ferrera P., Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004, 28:505-510.
17. Enting R.H., Oldenmenger W.H., van der Rijt C.C., et al. Nitrous oxide is not beneficial for breakthrough cancer pain. Palliat Med 2002, 16:257-259.
18. Mercadante S., Arcuri E., Tirelli W., Casuccio A. The analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000, 20:246-252.
19. del Rosario M.A., Martin A.S., Ortega J.J., Feria M. Temporary sedation with midazolam for control of severe incident pain. J Pain Symptom Manage 2001, 21:177-178.
20. Hanks G.W., De Conno F., Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84:587-593.
21. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patients' assessment of time to meaningful pain relief. J Pain Symptom Manage 2008, 35:563-567.
22. Collins S.L., Faura C.C., Moore R., McQuay H.J. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998, 16:388-402.
23. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Pall Care 2001, 8:6-9.
24. Farrar J.T., Cleary J., Rauch R., Busch M., Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blind, placebo-controlled trial for the treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998, 90:611-616.
25. Coluzzi P.H., Schwartzberg L., Conroy J.D., et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001, 91:123-130.
26. Payne R., Coluzzi P., Hart L., et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001, 22:575-583.
27. Pather S.I., Siebert J.M., Hontz J., et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Delivery Technol 2001, 1:54-57.
28. Darwish M., Kirby M., Robertson P., et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007, 47:343-350.
29. Portenoy R.K., Taylor D., Messina J., Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006, 22:805-811.
30. Slatkin N.E., Xie F., Messina J., et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007, 5:327-334.
31. Weinstein S.M., Messina J., Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain. Cancer 2009, 115:2571-2579.
32. Bredenberg S., Duberg M., Lennernäs B., et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003, 20:327-334.
33. Lennernäs B., Hedner T., Holmberg M., Bredenberg S., Nyström C., Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004, 59:249-253.
34. Rauck R.L., Tark M., Reyes E., et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009, 25:2877-2885.
35. Accessed 22.11.2010. http://www.biodeliverysciences.com/BEMA.php.
36. Accessed 22.11.2010. http://www.biodeliverysciences.com/onsolis.php.
37. Rauck R., North J., Gever L.N., Tagarro I., Finn A.L. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010, 21:1308-1314.
38. Kaasa S., Moksnes K., Nolte T., Lefebvre-Kuntz D., Popper L., Kress H.G. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010, 6:17-26.
39. Kress H.G., Orońska A., Kaczmarek Z., Kaasa S., Colberg T., Nolte T. Efficacy and tolerability of fentanyl intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, double-blind, randomized, placebo-controlled cross-over trial with a 10-month open-label extension treatment period. Clin Ther 2009, 31:1177-1191.
40. Portenoy R.K., Burton A.W., Gabrail N., Taylor D. Fentanyl pectin nasal spray 043 study group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010, 151:617-624.